Onbrez
(Indacaterol)ApprovedSmall molecule
NovartisIndacaterol is used to treat chronic obstructive pulmonary disease (COPD) and helps open up the airways in the lungs to make breathing easier.[2] Onbrez is currently approved and in use across 6 indications[4].[1]
Onbrez is one of 156 small molecule programs targeting Hepatic failure. It is currently in Approved.
6
Indications
76
Total Trials
0
Active Trials
155
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Onbrez
NovartisApproved
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Aciphex
Akero TherapeuticsPreclinical
Atrovent
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease29 trials
Show 26 more trials
Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)
Completed·—·Phase 4·NCT02872090·42 enrolled
Asthma14 trials
Show 11 more trials
Efficacy7 trials
Efficacy and Safety5 trials
COPD5 trials
14 more indications
MPA2 trials
Budesonide1 trial
Salmeterol1 trial
Satisfaction1 trial
Adult Subject1 trial
Function1 trial
Unspecified2 trials
Regulatory
FDA Approval Timeline[5]
Jul 1, 2011
ARCAPTA NEOHALER
NDA NDA022383
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Onbrez drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Indacaterol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Onbrez. U.S. Food & Drug Administration.
- [7]